Intrauterine contraception has changed over the past decade through longer validated duration, lower-dose hormonal devices, redesigned copper devices, new indications, and better safety surveillance. This targeted scoping review (OSF registration 10.17605/OSF.IO/3GUQF) mapped English-language primary human studies published from 1 January 2016 to 5 September 2026 in journals indexed in the Science Citation Index Expanded (SCIE). A reproducible search targeted to the major device programs, randomized trials, and large surveillance cohorts identified 766 PubMed/MEDLINE records, with no additional unique records from Scopus or Web of Science; of the 624 unique records screened, 123 reports were assessed, and 114, from 66 distinct trials, cohorts, or data sources, were included and appraised with design-specific Joanna Briggs Institute (JBI) tools. Two single-arm programs and a 7-year randomized trial supported the efficacy of 52 mg levonorgestrel intrauterine devices (LNG-IUDs) through 8 years. Lower-dose LNG-IUDs eased placement but were associated with higher ectopic pregnancy rates in four Scandinavian analyses and with less antidepressant use than the 52 mg device. Smaller or size-matched copper devices improved continuation and reduced expulsion in randomized comparisons, whereas a low-copper nitinol device had a higher 5-year pregnancy rate than expected with TCu380A. Perforation was uncommon but more frequent after postpartum insertion and during breastfeeding; immediate postpartum insertion carried the highest expulsion risk. One randomized trial and its secondary analyses supported the 52 mg LNG-IUD for emergency contraception. Therapeutic evidence was strongest for heavy menstrual bleeding and endometrial hyperplasia, whereas intrauterine ball and precious metal designs showed no consistent benefit. Progress refined rather than replaced the T-shaped IUD.

Background and Objectives: Severe asthma poses significant clinical and economic burdens, with adherence to monitoring and treatment remaining a challenge despite biologic therapies. This pilot study aimed to evaluate the feasibility of telemedicine-based home monitoring using the AioCare system in patients with severe asthma and to determine if weekly reminder messages improved adherence compared to standard monitoring. Materials and Methods: In this prospective, single-center randomized controlled pilot study, 30 adults with severe asthma were assigned to either a reminder group (weekly SMS or in-app messages) or a control group without reminders. All participants performed weekly home spirometry for 12 weeks using the AioCare system. Lung function parameters, Asthma Control Test (ACT) scores, adherence to monitoring, and patient satisfaction were assessed. Longitudinal data were analyzed using mixed-effects and generalized estimating equation models. Results: Adherence to home monitoring was significantly higher in the reminder group (11.47 ± 0.92 vs. 9.13 ± 3.16 sessions; p = 0.044). Overall, patient satisfaction was higher in the intervention group (p = 0.0044), with universal endorsement of the reminders and perceived educational benefit. No significant between-group differences were observed in lung function parameters. ACT scores showed a favorable trend in both groups, with a medium between-group effect size favoring the intervention (d = 0.42), although this did not reach statistical significance. Conclusions: Home monitoring with reminders is feasible, safe, and enhances adherence and satisfaction in severe asthma, although it did not significantly affect short-term changes in lung function or symptom control. Larger, longer-term studies are warranted to determine whether these engagement benefits translate into improved long-term clinical outcomes.

Background/Objectives: Menopausal symptoms can impair quality of life and influence healthcare use. This study examined symptom burden, menopause-specific quality of life, healthcare seeking, consultation delay, treatment satisfaction, and associated demographic and clinical factors among Romanian women. Methods: This cross-sectional study included 204 peri- and postmenopausal women. We assessed symptoms and quality of life using the Menopause Rating Scale (MRS) and the Menopause-Specific Quality of Life Questionnaire (MENQOL). We compared groups, ran Spearman correlations, and used multivariable linear regression to identify demographic and clinical factors associated with MENQOL. We excluded MRS from the regression because of construct overlap, and restricted delay analyses to care seekers. Results: Care seekers had higher MRS (18.0 vs. 14.5; p = 0.041) and MENQOL scores (3.95 vs. 3.26; p = 0.009). MRS and MENQOL were strongly correlated (ρ = 0.858; p < 0.001), but consultation delay was not associated with either outcome among care seekers. In the adjusted model, higher BMI, postmenopausal stage, greater comorbidity burden, and menopause-medication use were associated with poorer quality of life (adjusted R² = 0.138). Treatment-satisfaction correlations were inverse but exploratory. Conclusions: Menopause-specific quality of life varied according to body composition, reproductive stage, general health burden, and treatment context. Clinical assessment should integrate these factors and review persistent symptoms among treated women. The cross-sectional findings do not establish causality or treatment effectiveness.

Background: An age of 45 years is often used to guide endometrial assessment in abnormal uterine bleeding (AUB), but age is only one component of clinical risk. We described the relationship between age and histopathological yield among premenopausal women who had undergone endometrial sampling. Methods: This single-centre retrospective cross-sectional study analysed the index sampling episodes of 824 women with AUB documented as premenopausal or perimenopausal (January 2022–May 2026). The clinically more consequential endpoint was endometrial intraepithelial neoplasia (EIN)/atypical hyperplasia or carcinoma; the primary statistical outcome was a broader composite that also included hyperplasia without atypia. Modified Poisson regression estimated the adjusted association between age ≥45 years and the primary outcome. Discrimination of age alone and of an exploratory model using variables available before biopsy was compared in 776 complete cases with bootstrap internal validation. Results: EIN/carcinoma occurred in 4/361 (1.1%) women aged <45 years and 25/463 (5.4%) aged ≥45 years (crude RR 4.87, 95% CI 1.71–13.88). The broad outcome occurred in 24/361 (6.6%) and 57/463 (12.3%), respectively (absolute difference 5.7 percentage points, 95% CI 1.6–9.6; adjusted RR 1.62, 95% CI 1.01–2.61; p = 0.047). Results were similar across sensitivity analyses (adjusted RRs 1.52–1.68). With age coded as ≥45 years in both models, the optimism-corrected AUC was 0.686 for the exploratory pre-biopsy model and 0.575 for age alone (difference 0.111, 95% CI 0.060–0.196). Conclusions: Among premenopausal women selected for endometrial sampling, histopathological yield increased with age, and most EIN/carcinoma cases occurred at age ≥45 years, but the adjusted association for the broad outcome was imprecise, and age alone had limited discrimination. Model performance was assessed only internally and only in sampled women; this study cannot establish a biopsy rule for all women with AUB because women not sampled were not observed.

Background: Psychological distress during menopause may reflect the combined influence of symptom burden and psychological resources. This study examined the concurrent conditional associations of nonpsychological menopausal symptom burden and general self-efficacy with anxiety and depressive symptom severity. Methods: This cross-sectional study included 247 peri- and postmenopausal women recruited from hospital and community settings in Timișoara, Romania. Participants completed the Hospital Anxiety and Depression Scale, Menopause Rating Scale, Menopause-Specific Quality of Life Questionnaire, General Self-Efficacy Scale, and COPE Inventory. Associations were examined using Spearman correlations and multivariable linear regression with HC3 robust inference. Results: At least borderline anxiety and depressive symptoms were identified in 54.7% and 42.5% of participants, respectively. In the fully adjusted psychological-resource models, greater nonpsychological menopausal symptom burden was associated with higher anxiety (β = 0.311, p < 0.001) and depression scores (β = 0.239, p < 0.001). Higher general self-efficacy was associated with lower anxiety (β = −0.169, p = 0.009) and depression scores (β = −0.319, p < 0.001). Although self-reported surgical menopause was associated with lower anxiety and depression scores relative to early perimenopause in the primary models, these associations were attenuated and no longer statistically significant in the restricted sensitivity analysis. Conclusions: Nonpsychological menopausal symptom burden and general self-efficacy were concurrent conditional correlates of anxiety and depressive symptom severity. The cross-sectional design does not establish temporal direction or causal effects, and the surgical-menopause finding should not be interpreted as protective.